5-MeO-AET

Summary

5-Methoxy-alpha-ethyltryptamine, often referred to as 5-MeO-α-ET, is a psychoactive substance belonging to the tryptamine chemical class. It is known to induce both psychedelic and stimulant effects.

Identifiers
IUPAC name
CAS Number4765-10-0 
ChemSpider21106244 
UNIIQCQ6JFX5NL
CompTox Dashboard (EPA)DTXSID20894761
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1

Effects

5-MeO-α-ET induces entactogenic and stimulant effects with a typical duration of 4 to 6 hours. It’s important to note that limited research is available regarding the psychopharmacological products of this compound, resulting in potential variations in dosage and impact among users.

Dangers

While there have been no documented fatalities or hospital admissions linked to 5-MeO-α-ET, it’s crucial to recognize that its safety profile remains uncertain.

Legality

5-MeO-α-ET is not subject to scheduling or regulation in the United States. However, it’s important to note that possession and distribution of 5-MeO-α-ET may potentially be subject to prosecution under the Federal Analog Act due to its structural resemblance to α-ET and α-MT.

FAQ

  • What is 5-MeO-α-ET?
  • 5-MeO-α-ET, or 5-Methoxy-alpha-ethyltryptamine, is a psychoactive compound belonging to the tryptamine class. It is known to produce entactogenic and stimulant effects.
  • What are the effects of 5-MeO-α-ET?
  • The effects of 5-MeO-α-ET typically include entactogenic (empathogenic) and stimulant effects, which can last for approximately 4 to 6 hours.
  • Is 5-MeO-α-ET safe to use?
  • The safety profile of 5-MeO-α-ET is mainly unknown. While there have been no reported deaths or hospitalizations associated with its use, it is essential to approach any psychoactive substance with caution, given the lack of comprehensive safety data.
  • Is 5-MeO-α-ET legal in the United States?
  • As of now, 5-MeO-α-ET is unscheduled and unregulated in the United States. However, its possession and distribution could potentially be subject to prosecution under the Federal Analog Act because of its structural similarities to other controlled substances.
  • Are there any known medical uses for 5-MeO-α-ET?
  • 5-MeO-α-ET was initially explored for its potential antidepressant properties but was withdrawn due to concerns about adverse effects. It is not approved for any medical use.
  • Is 5-MeO-α-ET the same as 5-MeO-DMT?
  • No, 5-MeO-α-ET is distinct from 5-MeO-DMT. While both are tryptamines, they have different chemical structures and effects.
  • What should I be cautious about when considering 5-MeO-α-ET use?
  • Since there is limited information available regarding its effects and safety, users should exercise extreme caution. It’s essential to be aware of potential risks, including unforeseen adverse reactions and legal consequences.
  • Is 5-MeO-α-ET addictive?
  • There is insufficient information to conclude whether 5-MeO-α-ET has addictive properties. As with any psychoactive substance, it’s essential to use it responsibly and be aware of potential risks.
  • Can 5-MeO-α-ET be detected in standard drug tests?
  • Since it is not commonly included in standard drug panels, 5-MeO-α-ET may not be detected in routine drug tests. However, specialized tests could potentially identify its presence.
  • Where can I find more information about 5-MeO-α-ET?
  • You can explore reputable sources of scientific literature or consult with healthcare professionals for more information about 5-MeO-α-ET. Additionally, you may find relevant information in online drug-related forums or harm reduction organizations. Always prioritize safety and informed decision-making.

References

  1. Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). “Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Elsevier BV. 39 (2): 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID22841965. S2CID22296279.

Leave a Comment

Your email address will not be published. Required fields are marked *